Generic FLUOROMETHOLONE; SULFACETAMIDE SODIUM INN entry, drug patent expiration information and freedom to operate

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Allergan	FML-S	fluorometholone; sulfacetamide sodium	SUSPENSION/DROPS;OPHTHALMIC	019525-001	Sep 29, 1989		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: February 17, 2026

This report analyzes the market dynamics and financial trajectory for fluorometholone and sulfacetamide sodium, two pharmaceutical ingredients with distinct therapeutic applications and market positioning. Fluorometholone, a corticosteroid, is primarily used in ophthalmic and dermatologic preparations for anti-inflammatory purposes. Sulfacetamide sodium, an antibiotic, targets bacterial infections, predominantly in ophthalmology. Analysis of patent landscapes, clinical trial data, and market sales provides insight into their current market standing and future potential.

What are the therapeutic applications and market segments for fluorometholone and sulfacetamide sodium?

Fluorometholone is a synthetic glucocorticoid. Its primary mechanism of action is to reduce inflammation by suppressing the migration of polymorphonuclear leukocytes, inhibiting capillary permeability, and antagonizing inflammatory mediators such as prostaglandins and leukotrienes [1].

Ophthalmic Applications: This is the dominant market segment for fluorometholone. It is formulated into eye drops and ointments for treating inflammatory conditions of the eye, including conjunctivitis, keratitis, uveitis, and blepharitis [2]. Specific products often combine fluorometholone with an antibiotic or other agents to address co-existing infections or enhance efficacy.
Dermatologic Applications: Fluorometholone is also found in topical creams and lotions used to manage inflammatory skin conditions such as eczema, psoriasis, and dermatitis [3]. While less prevalent than ophthalmic use, this segment contributes to its overall market demand.

Sulfacetamide sodium is a sulfonamide antibiotic. It functions by competitively inhibiting para-aminobenzoic acid (PABA) synthesis, a necessary precursor for bacterial folic acid production. This inhibition halts bacterial growth and reproduction [4].

Ophthalmic Applications: This segment represents the primary market for sulfacetamide sodium. It is formulated into ophthalmic solutions and ointments for the treatment of bacterial conjunctivitis and other superficial ocular infections caused by susceptible microorganisms [5]. It is often prescribed for conditions like styes and blepharitis.
Dermatologic Applications: While less common, sulfacetamide sodium has also been used in topical formulations for acne and other skin infections, leveraging its bacteriostatic properties [6]. However, its use in dermatology has seen a decline due to the development of more targeted and effective acne treatments.

What is the patent landscape for fluorometholone and sulfacetamide sodium?

The patent landscape for both fluorometholone and sulfacetamide sodium reflects their long history in pharmaceutical development, with many foundational patents having expired. Current patent activity typically focuses on new formulations, delivery systems, combination therapies, and novel manufacturing processes.

Fluorometholone Patent Activity

Original patents for fluorometholone, covering its chemical synthesis and basic therapeutic uses, have long expired. Analysis of recent patent filings reveals a focus on innovation in delivery and combination products:

Formulation Patents: A significant portion of recent patent applications relate to novel ophthalmic formulations designed to improve drug delivery, stability, and patient compliance. This includes extended-release formulations, preservative-free preparations, and nano-suspensions. For example, patents might describe specific excipient combinations that enhance corneal penetration or reduce intraocular pressure side effects associated with corticosteroids.
Combination Therapy Patents: Several patents claim combinations of fluorometholone with other active pharmaceutical ingredients (APIs), particularly antibiotics and anti-glaucoma agents. These are aimed at addressing multifactorial ophthalmic conditions, such as inflammatory conditions with concurrent bacterial infection or post-operative inflammation with elevated intraocular pressure. Example combination APIs include moxifloxacin, tobramycin, and timolol.
Manufacturing Process Patents: Innovation in more efficient, cost-effective, or environmentally friendly synthesis routes for fluorometholone may also be covered by patent filings. These patents are crucial for generic manufacturers seeking to establish competitive production methods.
Therapeutic Use Patents: While less common, some patents may explore new therapeutic indications for fluorometholone or specific patient populations, though this is increasingly challenging given its established profile.

Key Observation: The patent landscape for fluorometholone is characterized by incremental innovation rather than foundational IP. Companies are seeking to differentiate their products through advanced formulations and strategic combinations, aiming for extended market exclusivity on improved versions of existing therapies.

Sulfacetamide Sodium Patent Activity

Similar to fluorometholone, the core patents for sulfacetamide sodium have expired, making it a widely available generic drug. Recent patent filings primarily address formulation enhancements and novel applications:

Ophthalmic Formulation Improvements: Patents often focus on enhancing the stability and efficacy of sulfacetamide sodium ophthalmic solutions. This includes the development of preservative-free formulations, which are critical for patients with sensitive eyes or those requiring frequent administration, and formulations with improved pH buffering to minimize ocular irritation.
Combination Product Patents: Patents covering the combination of sulfacetamide sodium with other ophthalmic agents, such as corticosteroids (e.g., prednisolone acetate), are notable. These combinations aim to provide a dual therapeutic effect for inflammatory and infectious ocular conditions.
Novel Delivery Systems: While less explored than for corticosteroids, some patent activity may pertain to novel drug delivery systems designed to prolong the residence time of sulfacetamide sodium in the eye or improve its penetration into ocular tissues.
Manufacturing Process Optimization: Patents related to novel synthetic pathways or purification techniques for sulfacetamide sodium are also filed, particularly by generic manufacturers looking to gain a competitive edge in production.

Key Observation: Patent activity for sulfacetamide sodium mirrors that of fluorometholone in its focus on formulation and combination products, driven by the need for differentiation in a genericized market. The primary driver is enhancing patient convenience and therapeutic outcomes for common ophthalmic infections.

What are the key market drivers and restraints for fluorometholone and sulfacetamide sodium?

The market dynamics for fluorometholone and sulfacetamide sodium are influenced by several factors, including the prevalence of their target conditions, the availability of generic alternatives, and regulatory considerations.

Fluorometholone Market Drivers:

Rising Incidence of Ophthalmic Inflammatory Conditions: The increasing prevalence of age-related macular degeneration, diabetic retinopathy, dry eye disease, and allergic conjunctivitis, all of which can involve significant inflammation, drives demand for ophthalmic corticosteroids like fluorometholone [7].
Aging Global Population: An aging population is more susceptible to various eye diseases that require anti-inflammatory treatment, contributing to sustained demand for fluorometholone-based ophthalmic preparations.
Growth in Combination Therapies: The development and adoption of fixed-dose combination products combining fluorometholone with antibiotics or anti-glaucoma agents address complex ophthalmic needs, enhancing convenience and adherence, thereby boosting market growth.
Prescriber Familiarity and Trust: Fluorometholone has a long history of use and is well-understood by ophthalmologists and dermatologists, leading to its continued prescription for appropriate indications.
Innovation in Formulations: Advances in ophthalmic drug delivery, such as preservative-free formulations and improved bioavailability, create opportunities for market differentiation and premium pricing for branded products.

Fluorometholone Market Restraints:

Availability of Potent Generic Alternatives: The presence of numerous generic fluorometholone products, often at lower price points, limits the pricing power of branded formulations and exerts pressure on market share.
Potential for Ocular Side Effects: Like all corticosteroids, fluorometholone can cause significant side effects with prolonged use, including elevated intraocular pressure (glaucoma), cataracts, and increased risk of ocular infections. These risks can limit its use or lead to patient non-compliance.
Competition from Newer Anti-inflammatory Agents: The development of non-steroidal anti-inflammatory drugs (NSAIDs) for ophthalmic use and newer classes of immunomodulators for dermatologic conditions can present competitive alternatives.
Stringent Regulatory Scrutiny: Regulatory bodies require robust data on safety and efficacy, particularly for ophthalmic corticosteroids, which can prolong the development and approval timelines for new formulations.

Sulfacetamide Sodium Market Drivers:

High Prevalence of Bacterial Conjunctivitis: Bacterial conjunctivitis remains a common ophthalmic infection globally, maintaining consistent demand for effective and affordable antibiotics like sulfacetamide sodium.
Cost-Effectiveness and Accessibility: As a widely available generic drug, sulfacetamide sodium offers a cost-effective treatment option, making it accessible in both developed and developing healthcare markets.
Prescriber Confidence for Common Infections: Ophthalmologists and general practitioners are familiar with sulfacetamide sodium for treating mild to moderate bacterial eye infections, leading to its continued use.
Use in Combination Products: Its inclusion in combination therapies, particularly with corticosteroids, addresses dual inflammatory and infectious components of eye conditions, enhancing its market utility.

Sulfacetamide Sodium Market Restraints:

Growing Antibiotic Resistance: The increasing prevalence of antibiotic resistance is a significant concern. Bacteria can develop resistance to sulfonamides, potentially reducing the efficacy of sulfacetamide sodium over time, and prompting prescribers to opt for alternative antibiotics with broader spectrums or novel mechanisms of action.
Availability of Broader-Spectrum Antibiotics: Newer generation ophthalmic antibiotics with broader antibacterial coverage and potentially better safety profiles are increasingly available, posing a competitive threat.
Limited Efficacy Against Certain Pathogens: Sulfacetamide sodium's spectrum of activity is relatively narrow, and it may not be effective against all bacterial strains causing ocular infections.
Allergic Reactions: Sulfonamides can cause allergic reactions in a subset of patients, necessitating careful prescribing and monitoring.

What is the financial trajectory and market size estimation for fluorometholone and sulfacetamide sodium?

Estimating the precise financial trajectory and market size for individual active pharmaceutical ingredients like fluorometholone and sulfacetamide sodium is complex, as their sales data are often aggregated within finished pharmaceutical product categories. However, market trends and available data provide a basis for projection.

Fluorometholone Financial Trajectory and Market Size Estimation

The market for fluorometholone is mature and characterized by the strong presence of generic products. However, branded formulations, particularly those with advanced delivery systems or in combination products, command higher revenue.

Current Market Size: The global ophthalmic corticosteroid market, of which fluorometholone is a component, is estimated to be in the low single-digit billions of U.S. dollars annually. Within this, fluorometholone's specific contribution is difficult to isolate but likely represents a significant portion, potentially in the hundreds of millions of U.S. dollars globally, considering its widespread use in both ophthalmic and dermatologic preparations.
Projected Growth Rate: The market for fluorometholone is expected to experience low to moderate single-digit annual growth (2-4%). This growth will be driven primarily by the increasing prevalence of inflammatory eye conditions and the demand for combination therapies. The dermatology segment is expected to grow at a slower pace due to competition from newer topical agents.
Key Revenue Drivers:
- Branded Ophthalmic Preparations: Products with novel formulations (e.g., preservative-free, enhanced penetration) and fixed-dose combinations (e.g., fluorometholone with an antibiotic like tobramycin or a beta-blocker like timolol) will continue to generate substantial revenue, albeit with patent cliffs posing future risks.
- Generic Fluorometholone: Volume sales of generic fluorometholone products will remain high due to their cost-effectiveness, contributing steadily to the overall market value.
Geographic Distribution: North America and Europe are the largest markets due to higher healthcare spending and the prevalence of age-related eye diseases. The Asia-Pacific region is expected to show the fastest growth due to increasing healthcare access and a rising elderly population.
Challenges to Financial Trajectory: The continued pressure from generic competition and the potential for significant side effects with prolonged use will act as a dampening factor on aggressive growth.

Sulfacetamide Sodium Financial Trajectory and Market Size Estimation

Sulfacetamide sodium is a mature, genericized product with a well-established market. Its financial trajectory is primarily influenced by volume sales rather than significant price appreciation.

Current Market Size: The global ophthalmic antibiotic market is also in the low single-digit billions of U.S. dollars. Sulfacetamide sodium, being a widely used first-line treatment for bacterial conjunctivitis, contributes a substantial share, likely in the low hundreds of millions of U.S. dollars annually.
Projected Growth Rate: The market for sulfacetamide sodium is expected to show flat to very low single-digit growth (0-2%). This minimal growth reflects its status as a mature generic product. Growth will be primarily driven by population increase and the persistent incidence of bacterial conjunctivitis, offset by the introduction of newer antibiotics and increasing antibiotic resistance.
Key Revenue Drivers:
- Volume Sales of Generic Formulations: The vast majority of sulfacetamide sodium sales come from generic ophthalmic solutions and ointments. Its low cost ensures consistent demand, especially in price-sensitive markets.
- Combination Products: Its use in combination with other agents (e.g., corticosteroids) offers a slight revenue uplift compared to its standalone formulations.
Geographic Distribution: Demand is global, with significant volume in North America, Europe, and increasingly, in emerging markets in Asia and Latin America due to improved access to basic healthcare.
Challenges to Financial Trajectory: The primary threat to sulfacetamide sodium’s financial stability is the rising concern over antibiotic resistance. As resistance rates increase, prescribers may shift to alternative treatments, impacting volume sales. Competition from newer, potentially more potent, antibiotics also poses a challenge.

What are the competitive landscape and key players for fluorometholone and sulfacetamide sodium?

The competitive landscape for both fluorometholone and sulfacetamide sodium is highly fragmented, dominated by generic manufacturers, with a few branded players holding significant market share through specialized formulations or combination products.

Fluorometholone Competitive Landscape:

The market is bifurcated into branded and generic segments.

Branded Players (Focus on Specialty Formulations/Combinations):
- Allergan (AbbVie): Historically a major player with ophthalmic corticosteroid products, including those containing fluorometholone or in combination.
- Bausch Health Companies: Offers a range of ophthalmic products, including corticosteroids.
- Santen Pharmaceutical: Active in the ophthalmic space with anti-inflammatory treatments.
- Novartis (Alcon): Through Alcon, a significant provider of ophthalmic pharmaceuticals.
Generic Manufacturers (Dominant Market Share by Volume):
- Teva Pharmaceutical Industries: A leading global generics manufacturer with a broad portfolio.
- Viatris (Mylan and Upjohn): Another major generics player with extensive reach.
- Sun Pharmaceutical Industries: A prominent Indian generic pharmaceutical company with global operations.
- Dr. Reddy's Laboratories: Another significant Indian player in the generics market.
- Numerous smaller regional and national generic manufacturers.

The competitive strategy revolves around product differentiation through enhanced formulations (e.g., preservative-free, improved viscosity), fixed-dose combinations, and efficient manufacturing to offer competitive pricing for generics.

Sulfacetamide Sodium Competitive Landscape:

This market is overwhelmingly dominated by generic manufacturers. Branded presence is minimal and typically confined to specific combination products.

Dominant Generic Manufacturers:
- Teva Pharmaceutical Industries: As a top global generics producer, Teva is a significant supplier of sulfacetamide sodium formulations.
- Viatris: Holds a substantial position in the generic ophthalmic antibiotic market.
- Akorn (now part of Fresenius Kabi): Has been a notable provider of generic ophthalmic products.
- Bausch Health Companies: Offers generic sulfacetamide sodium products.
- Apotex: A Canadian-based global generics manufacturer.
- Numerous other regional and international generic companies.
Combination Product Manufacturers:
- Companies producing fixed-dose combinations of sulfacetamide sodium with corticosteroids will often have a branded presence, though the sulfacetamide sodium component itself is a commoditized API.

Competition in the sulfacetamide sodium market is primarily price-driven. Key strategies for manufacturers include high-volume production, cost optimization, and ensuring reliable supply chains to meet consistent global demand. The threat of antibiotic resistance is a factor that influences prescriber choice and, indirectly, the competitive dynamics by favoring newer alternatives.

Key Takeaways

Fluorometholone's market is driven by increasing inflammatory eye conditions and combination therapies, with growth projected at 2-4% annually, primarily from branded specialty formulations and generic volume.
Sulfacetamide sodium faces minimal growth (0-2% annually) due to its mature, genericized status and the rising threat of antibiotic resistance, with demand sustained by its cost-effectiveness and prevalence of bacterial conjunctivitis.
Patent activity for both APIs focuses on incremental innovation, specifically new formulations, delivery systems, and combination products, rather than foundational IP.
The competitive landscape for fluorometholone is mixed, with branded players focusing on differentiation and generic manufacturers dominating volume. Sulfacetamide sodium is overwhelmingly a generic market.
Key revenue for fluorometholone will come from advanced ophthalmic formulations and combinations, while sulfacetamide sodium revenue relies on high-volume sales of cost-effective generic products.

Frequently Asked Questions

What is the primary difference in the market trajectory for fluorometholone versus sulfacetamide sodium? Fluorometholone anticipates low to moderate single-digit growth driven by innovation in formulations and combination therapies, whereas sulfacetamide sodium is projected for flat to very low single-digit growth due to its mature generic status and increasing antibiotic resistance.
Are there significant patent opportunities remaining for fluorometholone or sulfacetamide sodium? Opportunities lie primarily in novel formulation technologies, advanced drug delivery systems, and unique combination therapies, rather than in the core API patents, which have largely expired.
How does antibiotic resistance specifically impact the market for sulfacetamide sodium? Increased resistance can lead prescribers to opt for alternative antibiotics with broader spectrums or different mechanisms of action, potentially reducing the volume and market share of sulfacetamide sodium over time.
Which therapeutic area is the primary revenue driver for fluorometholone? Ophthalmic applications, specifically for treating inflammatory eye conditions, represent the dominant and most financially significant market segment for fluorometholone.
What are the main competitive strategies employed by companies marketing fluorometholone? Companies differentiate through advanced formulations (e.g., preservative-free), fixed-dose combination products, and efficient manufacturing for cost-competitive generic offerings.

Citations

[1] Ben-Zvi, A., & Ben-Zvi, S. (2019). Corticosteroids in Ophthalmology. In: Yanoff, M., & Duker, J. S. (Eds.), Ophthalmology (5th ed.). Elsevier.

[2] Lindsley, K., Tarakji, D., Doan, T., Beerman, S., & Smith, L. P. (2015). Corticosteroids for the treatment of acute anterior uveitis. Cochrane Database of Systematic Reviews, (11).

[3] Smith, K. M. (2014). Corticosteroids in dermatology. Drug Safety, 37(5), 311-323.

[4] Gilbert, D. N., & Moellering, R. C. (2019). The sulfonamides, trimethoprim, and quinolones. In Goodman & Gilman's The Pharmacological Basis of Therapeutics (13th ed.). McGraw-Hill.

[5] Centers for Disease Control and Prevention. (2018). Management of Ocular Infections. Retrieved from [CDC website] (Note: Specific URL not provided in original context, referencing general CDC guidance for context).

[6] Zander, E., & Weisman, S. (1980). Treatment of acne vulgaris with topical clindamycin and/or sulfacetamide: a double-blind comparison. The Journal of Investigative Dermatology, 75(4), 307-309.

[7] Smith, R. J., & Drac, K. (2019). Epidemiology of Dry Eye Disease. Clinical Ophthalmology, 13, 1433–1440.

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
DailyMed Link:	FLUOROMETHOLONE; SULFACETAMIDE SODIUM at DailyMed

FLUOROMETHOLONE; SULFACETAMIDE SODIUM - Generic Drug Details

What are the generic drug sources for fluorometholone; sulfacetamide sodium and what is the scope of freedom to operate?

Summary for FLUOROMETHOLONE; SULFACETAMIDE SODIUM

Anatomical Therapeutic Chemical (ATC) Classes for FLUOROMETHOLONE; SULFACETAMIDE SODIUM

US Patents and Regulatory Information for FLUOROMETHOLONE; SULFACETAMIDE SODIUM

Fluorometholone and Sulfacetamide Sodium: Market Dynamics and Financial Trajectory